The effects of polygenic risk for psychiatric disorders and smoking behaviour on psychotic experiences in UK Biobank

Judit García-González[1*], Julia Ramírez[2], David M. Howard[3,4], Caroline H Brennan[1], Patricia B. Munroe[2,5†], Robert Keers[1†]

[†] Equally contributed

Affiliations: [1] School of Biological and Chemical Sciences, Queen Mary, University of London, London E1 4NS, UK. [2] Clinical Pharmacology, William Harvey Research Institute, Barts and The London School of Medicine and Dentistry, Queen Mary University of London, London, EC1M 6BQ, UK. [3] Social, Genetic and Developmental Psychiatry Centre, Institute of Psychiatry, Psychology and Neuroscience, King's College London, London, UK. [4] Division of Psychiatry, University of Edinburgh, Royal Edinburgh Hospital, Edinburgh, UK. [5] NIHR Barts Cardiovascular Biomedical Research Centre, Barts and The London School of Medicine and Dentistry, Queen Mary University of London, London, EC1M 6BQ, UK.

* Address correspondence to Judit García-González (j.garciagonzalez@qmul.ac.uk, +447598327404), School of Biological and Chemical Sciences, Queen Mary, University of London, London E1 4NS, UK.

Running title: Gene-smoking interplay in psychotic experiences

ABSTRACT

While psychotic experiences are core symptoms of mental health disorders like schizophrenia, they are also reported by 5-10% of the population. Both smoking behaviour and genetic risk for psychiatric disorders have been associated with psychotic experiences, but the interplay between these factors remains poorly understood. We tested whether smoking status, maternal smoking around birth, and number of packs smoked/year were associated with lifetime occurrence of three psychotic experiences phenotypes: delusions (n=2067), hallucinations (n=6689), and any psychotic experience (delusions or hallucinations; n=7803) in 144818 UK Biobank participants. We next calculated polygenic risk scores for schizophrenia (PRS_{SCZ}), major depression (PRS_{DEP}) and attention deficit hyperactivity disorder (PRS_{ADHD}) in the UK Biobank participants to assess whether association between smoking and psychotic experiences was attenuated after adjustment of diagnosis of psychiatric disorders and the PRSs. Finally, we investigated whether smoking exacerbates the effects of genetic predisposition on the psychotic phenotypes in gene-environment interaction models. Smoking status, maternal smoking, and number of packs smoked/year were significantly associated with psychotic experiences ($p<1.77x10^{-5}$). Except for packs smoked/year, effects were attenuated but remained significant after adjustment for diagnosis of psychiatric disorders and PRSs ($p<1.99x10^{-3}$). Gene-environment interaction models showed the effects of PRS_{DEP} and PRS_{ADHD} (but not PRS_{SCZ}) on delusions (but not hallucinations) were significantly greater in current smokers compared to never smokers ($p<0.0028$). There were no significant gene-environment interactions for maternal smoking nor for number of packs smoked/year. Our results suggest that both genetic risk of psychiatric disorders and smoking status may have independent and synergistic effects on specific types of psychotic experiences.

INTRODUCTION

Psychotic experiences, such as hallucinations (unreal visual or auditory perceptions) and delusions (unreal beliefs or impressions, i.e. conspiracy against self, unreal communications or signs), are reported by 5-10% of the general population (1). Psychotic experiences are core symptoms of severe mental disorders, such as schizophrenia, and therefore may be an indicator of risk for mental health problems even in apparently healthy individuals. Understanding their aetiology could help identify individual susceptibility for different mental health outcomes and develop tailored prevention and intervention strategies.

Genetic factors influence psychotic experiences, with genes explaining between 30-50% of the variance in twin studies (2,3) and common genetic variation explaining between 3-17% of the variance in molecular genetic studies (4,5). Twin studies also suggest that the genetic component of psychotic experiences is shared with psychiatric disorders such as schizophrenia, depression and attention deficit hyperactivity disorder (ADHD) (6). Large genome-wide studies of psychotic experiences in UK Biobank (UKB) confirm these findings: polygenic risk scores (PRS) of schizophrenia, depression, and ADHD explain 0.11%, 0.32%, and 0.05% of the variance in psychotic experiences, respectively (7). Linkage disequilibrium score regression (LDSC) indicates the genetic correlation estimates between psychotic experiences and schizophrenia, depression and ADHD are 0.21, 0.46 and 0.24 (7).

In addition to genetic influences, environmental factors explain between 50-70% of the variance in psychotic experiences (3). Smoking is one of the best established environmental risk factors associated with the occurrence of psychotic experiences in case-control studies of

schizophrenia and bipolar disorder, as well as in population-based samples. Longitudinal

studies suggest that continued smoking is a causal factor for psychotic experiences among

people with first episode of psychosis (8), schizophrenia, and bipolar disorder patients (9).

The observation of a dose-response effect in prospective studies (10–13), together with

recent Mendelian randomization studies (14), further support a causal effect of smoking on

the occurrence of psychotic experiences. In addition, the associations between lifetime

tobacco use and subsequent psychotic experiences (15,16) in the general population

remained significant after adjusting for other psychiatric disorders (16), suggesting that

smoking may lead to psychotic experiences independently from mental health status.

Associations between other smoking phenotypes and psychotic experiences are less well-

established: There is much less evidence for an increased risk of psychotic experiences in

former smokers, leading some to suggest that the effects of smoking are reversible (17,18).

However, it is still unclear whether these findings are false positives resulting from a lack of

power in relatively small samples. Maternal smoking during pregnancy is associated with

psychotic experiences in offspring (19). However within-family studies suggest that once

familial factors are taken into account, maternal smoking during pregnancy has no effect on

the risk of psychotic experiences (20).

Despite evidence showing associations between genetic risk for psychiatric disorders and

psychotic experiences (6,7) , and a number of studies showing associations between smoking

and psychotic experiences (17,21–23), the interplay between smoking and genetic risk on

psychotic experiences remains unknown. There are studies showing that PRSs for psychiatric

disorders are associated with smoking (24–27). This means that smoking may not be only a

casual factor in the development of psychotic experiences, but that common genetic factors

may affect both smoking and psychotic experiences. However, no studies have tested

whether PRSs for psychiatric disorders and smoking make independent contributions to

psychotic experiences. Significant gene-environment interactions (GxE) have been reported

for several psychiatric traits including schizophrenia and depression (28–30), but studies are

yet to explore whether there is an interaction between smoking and PRSs for psychiatric

disorders on psychotic experiences. That is, whether the effects of genetic risk are greater for

individuals exposed to smoking.

Our first objective was to investigate whether smoking status (current, former or never

smoker), number of packs smoked per year, and maternal smoking around birth were

associated with lifetime delusions or hallucinations or any psychotic experience (delusions or

hallucinations) in the UKB cohort. We also tested whether the effects of smoking remained

significant after adjustment for psychotic disorders, depression and ADHD, as well as genetic

risk for these disorders. Our second objective was to investigate whether the effects of

smoking on psychotic experiences were exacerbated by genetic risk by testing additive and

multiplicative GxE between these variables.

METHODS:

An overview of the study design is provided in Figure 1. First we performed main effect

analyses, where we examined the associations between smoking (smoking status, maternal

smoking, and number of packs smoked per year) and psychotic experiences (delusions,

hallucinations, or any of the two). We conducted two additional analyses including as

covariates diagnosis of psychotic disorders, depression and ADHD, as well as PRSs for

schizophrenia (PRS_{SCZ}), depression (PRS_{DEP}) and ADHD (PRS_{ADHD}), to test whether the effect of

smoking on psychotic experiences is independent of these psychiatric diagnoses and genetic

predisposition. To calculate the PRSs, we used genome-wide association studies (GWAS)

summary statistics from published meta-analyses of schizophrenia, depression and ADHD

(31–33).

We next analysed the interaction effects of smoking and PRSs on psychotic experiences. We

interrogated whether being a current, former or never smoker; smoking more packs of

cigarettes per year; or being exposed to maternal smoking around birth influenced the effects

of PRSs on having hallucinations, delusions, or any of the two. When significant interactions

between smoking and PRS were identified, we carried out sensitivity analyses excluding

people with psychotic disorders.

Figure 1. Detailed flowchart of the analytical approach. UKB: UK Biobank cohort. PRS: polygenic risk scores for schizophrenia (PRS_{SCZ}), depression (PRS_{DEP}), and ADHD (PRS_{ADHD}). GWA: genome wide association. ADHD: Attention deficit hyperactivity disorder.

UKB sample

The sample was drawn from UKB, a population-based cohort from the United Kingdom with ~500 000 participants. From those, 157 366 participants completed an online mental health questionnaire. A detailed description of the mental health questionnaire has been provided elsewhere (34). This research was conducted using the UK Biobank Resource under Application Number #42423.

Measures

Psychotic experiences

Psychotic experiences were categorised based on the Composite International Diagnostic

Interview included in the mental health questionnaire. Three outcomes were defined:

delusions, *hallucinations*, and *any psychotic experience*. Delusions were ascertained as

individuals reporting lifetime delusions of reference and/or persecutory delusions (Field IDs:

20474, 20468). Hallucinations were ascertained as individuals reporting lifetime visual and/or

auditory hallucinations (Field IDs: 20471, 20463). Any lifetime psychotic experiences were

ascertained as a positive response to any of the four symptom questions (Field IDs: 20474,

20468, 20471, 20463). Controls were defined as individuals that did not endorse lifetime

psychotic experiences. A more detailed description of the outcome variables is provided in

the Supplementary Tables 1-3.

Smoking

Three smoking outcomes were defined using the UKB baseline questionnaire: Smoking status

(Field ID 20116), pack years of smoking (Field ID 20161) and maternal smoking around birth

(Field ID 1787). The smoking status phenotype consisted of *never smoker*, *former smokers*

and *current smokers*. Pack years of smoking was calculated for former and current smokers

and it was defined as number of cigarettes smoked per day, divided by twenty, multiplied by

the number of years of smoking. Cases for maternal smoking were defined as individuals

endorsing "Yes" for the question *"Did your mother smoke regularly around the time when you*

were born?".

Other psychiatric disorders

Lifetime depression, ADHD, schizophrenia, mania, hypomania, bipolar or manic depression,

and any other type of psychotic disorder were defined using both the UKB baseline and

mental health questionnaires (Supplementary Tables 4 and 5).

UKB genetic dataset

The data release contained 488 377 individuals genotyped on either the UKB Axiom or the UK

BiLEVE Axiom arrays. Genotype data were imputed centrally by UKB with IMPUTE2 using the

Haplotype Reference Consortium panel (35). UKB also provided metrics for quality control

that were used to exclude individuals with poor genotype call rate (>5%) and discordance

between the self-reported sex and the sex inferred from the genotypes. The first two principal

components provided by UKB were used in a k-means clustering algorithm (36) to identify a

genetically homogeneous subsample. Related individuals were identified for each phenotype

separately using the R package 'ukbtools' (37) and one individual from related pairs/trios

were excluded (kinship coefficient > 0.0884). Details on the quality control (QC) of genetic

data and sample sizes after QC exclusion are provided in Supplementary Table 6.

PRSs

We calculated PRS_{SCZ}, PRS_{DEP} and PRS_{ADHD} for each UKB participant using the software PRSice-

2 (38) and summary statistics from three recent GWAS of these disorders (Supplementary

material) (31–33). Logistic regression models were used to explore the association between

PRS_{SCZ}, PRS_{DEP} and PRS_{ADHD} and psychotic experiences using PRSice-2 (38). Analyses included

the first ten principal components and genotyping batch as covariates.

Main effect analyses

Regression models were constructed to assess the association between maternal smoking,

smoking status and number of packs smoked per year and psychotic experiences. To test

whether the association between smoking and psychotic experiences was independent of

diagnosis for psychiatric disorders and genetic predisposition, models were rerun adjusting

for: diagnosis for psychotic disorders, depression, and ADHD, as well as the PRS with highest

predictive ability (p-value threshold = 0.2) on psychotic experiences.

Interaction effect analyses

We explored whether there were GxE between each of the PRSs and smoking on psychotic

experiences (i.e. whether the effects of genetic risk differed among current, former or never

smokers, among smokers that consumed more packs of cigarettes per year, and among

individuals whose mothers smoked around time of participants' birth). Interactions were

tested on the multiplicative and additive scales using logistic and linear regressions,

respectively. Interactions on the *multiplicative scale* assess whether the joint effect of the PRS

and smoking is greater than the *product* of their individual effects. Interactions on the *additive*

scale assess whether the joint effect of smoking and the PRS is greater than the *sum* of their

individual effects. Modelling multiplicative and additive GxE using linear and logistic

regressions has been described elsewhere (29,30,39).

In the GxE regression models, we included individuals from UKB with genetic, smoking and

psychotic experiences data (n = 143 320 for any psychotic experience, n = 143 043 for

hallucinations, and n = 143 245 for delusions). Independent variables were the PRS_{DEP},

PRS_{ADHD}, or PRS_{SCZ} for each individual, smoking phenotype, ten principal components and

genotyping batch. Dependent variables were lifetime occurrence of hallucinations, delusions

or any psychotic experience. Models also included the interaction of smoking and PRS with

genotyping batch and the principal components, to control for the effect of these covariates

on the interaction term (40). To examine whether the GxE was significant after multiple

testing correction ($p < 0.0028$ based on 18 models under additive and multiplicative models:

0.05/18 = 0.0028), we used the anova function from R package "car". All models were

constructed in R (version 3.5.1).

Sensitivity analyses

The inclusion of individuals with psychotic disorders (Supplementary Table 4) may inflate the

variance explained by the PRSs and lead to false positive GxE. Therefore, we repeated the

significant interaction effect analysis after excluding individuals that met criteria for psychotic

disorders.

RESULTS:

157 366 individuals completed the mental health questionnaire. From those, 2 067 reported

delusions, 6 689 hallucinations and 7 803 any psychotic experience. 953 individuals had both

lifetime delusions and hallucinations. Sample sizes for controls were 155 182, 150 336 and

149 289 for delusions, hallucinations, and any psychotic experience, respectively.

For the smoking variables derived from the full cohort, 273 542 individuals reported never

smoked, 173 072 being former smokers and 52 979 being current smokers. The mean number

of packs per year smoked was 23.4 (SD=18.8). 126 632 individuals reported that their mothers

had smoked around the participant's birth, whereas 306 266 reported the opposite. Table 1

includes demographic, psychiatric and behavioural characteristics of the sample *before*

genetic data QC. Supplementary Table 7 shows the number of individuals with psychotic

experiences stratified by smoking status, maternal smoking and mean number of packs

smoked per year *after* genetic data QC.

Table 1. Demographic, psychiatric and behavioural characteristics of the sample.

	Any psychotic experience		Delusions		Hallucinations	
	Cases *n = 7 803*	*Controls* *n = 149 289*	*Cases* *n = 2 067*	*Controls* *n = 155 182*	*Cases* *n = 6 689*	*Controls* *n = 150 336*
Age – [mean years (SD)]	54.6 (7.8)	56 (7.7)	53.8 (7.9)	55.9 (7.7)	54.7 (7.8)	56 (7.7)
Males N [%]	3 082 [39.5%]	64 940 [43.5%]	1 000 [48.4%]	67 193 [43.3%]	2 535 [37.9%]	65 546 [43.6%]
Behavioural/psychiatric during lifetime (Self-reported in Mental Health Questionnaire)						
Depression N [%]	4 627 [59.3%]	48 071 [32.2%]	1 482 [71.7%]	51 303 [33.06%]	3 860 [57.7%]	48 859 [32.5%]
ADHD N [%]	22 [0.28%]	100 [0.07%]	11 [0.53%]	122 [0.08%]	15 [0.22%]	115 [0.08%]

Schizophrenia N [%]		125 [1.60%]	0 [0%]	109 [5.27%]	46 [0.03%]	100 [1.49%]	55 [0.04%]
Mania, hypomania, bipolar or manic-depression N [%]		358 [4.59%]	423 [0.28%]	255 [12.34%]	573 [0.37%]	268 [4.00%]	556 [0.37%]
Any other type of psychosis or psychotic illness N [%]		358 [4.59%]	0 [0%]	272 [13.16%]	319 [0.21%]	270 [4.04%]	324 [0.22%]
Demographics							
Migrant [Yes %]		570 [7.3%]	9 554 [6.4%]	159 [7.7%]	9 932 [6.4%]	482 [7.2%]	9 622 [6.4%]
Adverse life experiences		7 077 [90.7%]	114 803 [76.9%]	1 914 [92.6%]	120 111 [77.4%]	6 060 [90.6%]	115 759 [77.0%]
Socio economic status (as per house ownership)	Own Outright N [%]	3 628 [46.5%]	82 557 [55.3%]	858 [41.5%]	85 350 [55.0%]	3 157 [47.2%]	82 985 [55.2%]
	Own Mortgage N [%]	3 074 [39.4%]	57 028 [38.2%]	804 [38.9%]	59 435 [38.3%]	2 622 [39.2%]	58 330 [38.8%]
	Rent social N [%]	523 [6.7%]	3 583 [2.4%]	190 [9.2%]	4 035 [2.6%]	441 [6.6%]	3 758 [2.5%]
	Rent private N [%]	328 [4.2%]	3 434 [2.3%]	132 [6.4%]	3 569 [2.3%]	261 [3.9%]	3 458 [2.3%]
	Accommodation rent free N [%]	86 [1.1%]	896 [0.6%]	27 [1.3%]	931 [0.6%]	74 [1.1%]	902 [0.6%]

Smoking and psychotic experiences

The odds of having delusions, hallucinations or any psychotic experience was significantly higher in current or former tobacco users when compared with non-users, and in participants whose mothers smoked around the time of birth (Table 2). There was a positive linear relationship between the number of packs of cigarettes and risk of psychotic experiences (Table 2). Associations between smoking and the likelihood of having psychotic experiences were strongest for continued tobacco smoking (current smoking vs never smoked). Associations were attenuated after adjustment for diagnosis of psychotic experiences, depression, and ADHD but remained significant. Only packs smoked per year on occurrence of delusions did not pass the significance threshold after multiple testing correction (p = 0.0125) (Table 2).

212 Table 2. Phenotypic relationships between smoking and psychotic experiences within UKB. Logistic regression models were used to assess the
213 association between smoking and three psychotic experiences phenotypes. OR; Odds ratio. *p*; p-value. Significance was declared at p < 0.0125
214 after Bonferroni correction (based on four tests, one per smoking phenotype).
215

	Unadjusted[a]		Adjusted for psychiatric disorders [b]		Adjusted for psychiatric disorders and PRS [c]	
	OR (95% CI)	*p*	OR (95% CI)	*p*	OR (95% CI)	*p*
Any psychotic experience						
Former vs never smoking	1.22 (1.16-1.28)	4.99×10^{-14}	1.16 (1.09-1.22)	5.67×10^{-8}	1.15 (1.09-1.21)	5.13×10^{-7}
Current vs never smoking	1.76 (1.62-1.91)	4.76×10^{-42}	1.47 (1.35-1.60)	3.32×10^{-19}	1.45 (1.33-1.58)	8.98×10^{-18}
Maternal smoking	1.26 (1.19-1.33)	5.89×10^{-17}	1.20 (1.14-1.27)	5.84×10^{-11}	1.19 (1.13-1.26)	6.93×10^{-10}
Packs smoked per year	1.006 (1.004-1.008)	4.61×10^{-7}	1.004 (1.001-1.006)	2.35×10^{-3}	1.003 (1.001-1.006)	5.85×10^{-3}
Delusions						
Former vs never smoking	1.28 (1.16-1.41)	1.68×10^{-6}	1.18 (1.06-1.30)	2.33×10^{-3}	1.16 (1.04-1.28)	6.19×10^{-3}
Current vs never smoking	2.21 (1.9-2.55)	9.74×10^{-27}	1.62 (1.39-1.88)	7.65×10^{-10}	1.58 (1.35-1.84)	5.70×10^{-9}
Maternal smoking	1.28 (1.15-1.42)	3.17×10^{-6}	1.20 (1.08-1.34)	7.55×10^{-4}	1.19 (1.06-1.32)	1.99×10^{-3}
Packs smoked per year	1.009 (1.005-1.013)	4.73×10^{-6}	1.005 (1.000-1.009)	0.032	1.004 (0.999-1.008)	0.063
Hallucinations						
Former vs never smoking	1.21 (1.14-1.28)	2.66×10^{-11}	1.15 (1.09-1.22)	1.22×10^{-6}	1.14 (1.08-1.20)	6.96×10^{-6}
Current vs never smoking	1.76 (1.61-1.92)	8.08×10^{-37}	1.49 (1.36-1.63)	2.08×10^{-18}	1.47 (1.34-1.61)	4.05×10^{-17}
Maternal smoking	1.26 (1.19-1.34)	4.47×10^{-15}	1.21 (1.14-1.28)	4.65×10^{-10}	1.20 (1.13-1.27)	3.81×10^{-9}
Packs smoked per year	1.005 (1.003-1.008)	1.77×10^{-5}	1.003 (1.001-1.006)	0.009	1.003 (1.001-1.006)	0.016

Note: For the predictor 'packs smoked per year' OR represents the increase in odds ratio *for one unit increase* in the number of packs smoked per year. Unadjusted model [a] assessed the
phenotypic relationship between psychotic experiences and smoking using logistic regression models. Adjusted model (b) included as covariates: diagnosis for psychotic disorders, ADHD and
depression. Adjusted model (c) included as covariates: diagnosis for psychotic disorders, depression and ADHD, as well as PRS for schizophrenia, PRS for depression and PRS for ADHD.

The PRS$_{SCZ}$, PRS$_{DEP}$, and PRS$_{ADHD}$ were significantly associated with psychotic experiences

(Supplementary Figure 1) and with smoking behaviour (Supplementary Figure 2). Therefore,

it is possible that genetic risk confounds the relationship between smoking and psychotic

experiences. To test this hypothesis, we included PRS$_{SCZ}$, PRS$_{ADHD}$ and PRS$_{DEP}$ as covariates in

the analyses. All the regression models (except packs smoked per year on delusions and

hallucinations) remained significant after the inclusion of the PRS$_{SCZ}$, PRS$_{ADHD}$, and PRS$_{DEP}$

(Table 2).

Interaction between genetic risk of psychiatric disorders and smoking on psychotic experiences

We found significant additive interactions between PRS$_{ADHD}$ and PRS$_{DEP}$ (but not PRS$_{SCZ}$) and

smoking status (current *vs* never smoker) on reporting lifetime delusions. That is, the

combined effect of PRS$_{ADHD}$ and smoking, or PRS$_{DEP}$ and smoking was significantly greater than

the sum of their individual effects (Figure 2 and Supplementary Table 8 for OR and β values).

However, there were no significant interactions between PRSs and smoking status for

hallucinations or any psychotic experiences (Figure 2).

To ensure that the significant interaction for PRS$_{ADHD}$ and PRS$_{DEP}$ was not entirely driven by

participants with a diagnosis of bipolar disorder or schizophrenia, we excluded individuals

meeting criteria for diagnosis of psychotic disorders (Supplementary Table 9) and repeated

the GxE analyses. All the interaction terms remained significant (Supplementary Figure 3 and

Supplementary Table 10).

There were no significant interactions between the PRSs and maternal smoking, nor between

the PRSs and number of packs per year (Supplementary Tables 11 and 12).

243
Figure 2. Associations between polygenic risk score for A) schizophrenia (PRS$_{SCZ}$), B)
depression (PRS$_{DEP}$), and C) ADHD (PRS$_{ADHD}$), and occurrence of psychotic experiences (PE)
under the additive model. Current smokers are shown as blue squares, former smokers as
orange triangles, and never smokers as green circles. P values for the PRS x smoking status
interactions are shown on the upper part of each plot. Significant associations (P<0.0028
based on 18 tests; 9 additive interactions and 9 multiplicative interactions) are highlighted in
bold. The effects of PRS$_{DEP}$ and PRS$_{ADHD}$ on the probability of having delusions are greater
among current smokers than former and never smokers.

DISCUSSION:

Our study investigated whether smoking is associated with the occurrence of psychotic experiences independently from diagnosis of psychotic disorders, depression or ADHD, or genetic predisposition for these disorders. We also tested whether the effects of smoking were modulated by the genetic risk in gene-environment interaction models. We found smoking status, maternal smoking and number of packs smoked per year were all significantly associated with increased risk of psychotic experiences. GxE modelling indicated the effects of two PRSs $_{(DEP\ \&\ ADHD)}$ on delusions was significantly greater in current smokers compared to never smokers. These results suggest both genetic risk and smoking behaviour contribute to specific types of psychotic experiences.

A few previous studies have assessed PRS-environment interactions on psychotic experiences finding that higher genetic risk exacerbates environmental effects. However, these studies have focused exclusively on genetic risk of schizophrenia and environmental factors such as stress (41) and birth weight (42). Our study is the first one to explore PRS by environment interactions with smoking on psychotic experiences and the first to explore these effects in the context of genetic risk of depression and ADHD. Further, our study had greater power than previous ones because we used at least 30 times larger sample sizes, we calculated multiple PRSs at higher p-values that increased the predictive power of the genetic score, and we used the largest GWAS summary statistics available to date.

The interaction of smoking status with PRS_{DEP}, but not with PRS_{SCZ}, on predicting delusions is of particular interest. Delusions of reference and persecution are classified as some of the

core symptoms of psychotic disorders (i.e. schizophrenia and bipolar disorder) but they are

rarely part of the diagnostic criteria for depression (43). Wooton et al (14) reported that

genetic risk for depression increased smoking, but there was unclear evidence for genetic risk

for schizophrenia increasing smoking. Our finding that PRS_{DEP} (but not PRS_{SCZ}) interacts with

smoking on predicting psychotic experiences points at a stronger relationship between

smoking and depression than between smoking and schizophrenia. Our sensitivity analyses,

where the interaction remained significant after excluding people with psychotic disorders,

supports this hypothesis.

In line with previous studies, we found significant associations between the smoking

phenotypes and psychotic experiences (10–13,17), and between PRS_{SCZ}, PRS_{DEP} and PRS_{ADHD}

and each of the smoking phenotypes and psychotic experiences (25,31,44,45). These findings

suggest that the relationship between the smoking variables and psychotic experiences may

be confounded by shared genetic influences. However, the effects of smoking remained very

similar after adjusting for PRSs, providing little evidence of genetic confounding by common

genetic variation associated with schizophrenia, depression and ADHD. Previous studies have

shown that the effects of smoking on psychotic experiences remain significant after

adjustment for psychiatric disorders (16). However, this is the first study to show these effects

also remain significant after adjustment for genetic risk of specific psychiatric disorders.

The effects of maternal smoking after adjusting for the PRSs are also interesting. Previous

within-family studies suggest that, once unmeasured familial factors are taken into account,

maternal smoking has little effect on psychotic disorders (20). In the current study, the effects

of maternal smoking persisted following adjustment for PRS_{SCZ}, PRS_{DEP} and PRS_{ADHD}. This

tentatively suggests that genetic risk for these disorders does not confound the relationship

between maternal smoking and psychotic experiences. Nevertheless, the PRSs tested only

capture a small fraction of the genetic risk for psychiatric disorders. Replication of these

effects using more powerful estimates of genetic risk will be required to test this hypothesis.

There are some limitations of this study: it is retrospective meaning it is subject to recalling

biases, which occur when participants do not accurately remember past experiences, and this

can lead to spurious results. We have relied on self-reported data, which might be affected

by different conceptions of what it is a psychotic experience. There were 351 individuals that

completed the UKB mental health questionnaire that may have also participated in the

Psychiatric Genomic Consortium cohorts analysed by Wray an colleagues (32). This overlap

was identified using a checksum-based approach as described in Howard et al (46) and the

impact over this overlap is unknown. We reported an interaction between genetic risk and

smoking, but the percentage of variance explained by the PRSs was very low (<1%), therefore

further work is required to understand the remaining sources of phenotypic variance. There

is also evidence of a "healthy volunteer" bias in UKB (47), especially among people who

completed the mental health questionnaire (34), which may make this study not fully

representative of the general population. Finally, the present study was focused on

individuals of European ancestry therefore these results might not be valid for other

ancestries (48).

Despite the limitations, we report for the first time that smoking is associated with occurrence

of psychotic experiences after adjusting for genetic risk for mental health, and that current

smokers with higher genetic risk for depression and ADHD are more likely to experience

delusions but not hallucinations. These results emphasise the importance of assessing

environmental and genetic factors jointly and separately, and exploring particular types of

psychotic experiences, as they can be differentially associated with smoking or other risk

factors. This study also highlights the relationship between smoking and depression, and

between smoking and ADHD on the occurrence of specific types of psychotic experiences in

the general population, encouraging further studies to explore the effect of genetic risk for

other psychiatric disorders on psychosis. Taken together, our results support the distinction

of types of psychotic symptoms, the inclusion of environmental factors, and the study of

cross-disorder genetic predictors to inform biological mechanisms underlying psychotic

experiences.

Acknowledgments: JGG is supported by a Queen Mary Principal's Research Studentship in the School of Biological and Chemical Sciences. DMH is supported by a Sir Henry Wellcome Postdoctoral Fellowship (Reference 213674/Z/18/Z) and a 2018 NARSAD Young Investigator Grant from the Brain & Behavior Research Foundation (Ref: 27404). PBM wishes to acknowledge support from the National Institutes of Health Research (NIHR) Cardiovascular Biomedical Centre at Barts and The London, Queen Mary University of London (QMUL). JR acknowledges support from the European Union's Horizon 2020 research and innovation programme under the Marie Sklodowska-Curie grant agreement No 786833. CHB acknowledges support from NIH grant No UO1 DA04440001A1. CHB is a member of the Royal Society Industry Fellows' College. RK is supported by Wellcome Trust Grant 208881/Z/17/Z.

Conflict of interests: The authors of this manuscript certify that they have NO affiliations with or involvement in any organization or entity with any financial interest.

REFERENCES

1. McGrath JJ, Saha S, Al-Hamzawi A, Alonso J, Bromet EJ, Bruffaerts R, et al. Psychotic Experiences in the General Population: A cross-national analysis based on 31,261 respondents from 18 countries. JAMA Psychiatry. 2015 Jul;72(7):697–705.

2. Zavos HMS, Freeman D, Haworth CMA, McGuire P, Plomin R, Cardno AG, et al. Consistent etiology of severe, frequent psychotic experiences and milder, less frequent manifestations: a twin study of specific psychotic experiences in adolescence. JAMA Psychiatry. 2014 Sep;71(9):1049–57.

3. Ronald A. Recent quantitative genetic research on psychotic experiences: new approaches to old questions. Current Opinion in Behavioral Sciences. 2015 Apr 1;2:81–8.

4. Sieradzka D, Power RA, Freeman D, Cardno AG, Dudbridge F, Ronald A. Heritability of individual psychotic experiences captured by common genetic variants in a community sample of adolescents. Behav Genet. 2015 Sep;45(5):493–502.

5. Ronald A, Pain O. A systematic review of genome-wide research on psychotic experiences and negative symptom traits: new revelations and implications for psychiatry. Hum Mol Genet. 2018 Aug 1;27(R2):R136–52.

6. Zavos HMS, Eley TC, McGuire P, Plomin R, Cardno AG, Freeman D, et al. Shared etiology of psychotic experiences and depressive symptoms in adolescence: a longitudinal twin study. Schizophr Bull. 2016 Sep;42(5):1197–206.

7. Legge SE, Jones HJ, Kendall KM, Pardiñas AF, Menzies G, Bracher-Smith M, et al. Association of Genetic Liability to Psychotic Experiences With Neuropsychotic Disorders and Traits. JAMA Psychiatry. 2019 Sep 25;

8. Myles N, Newall HD, Curtis J, Nielssen O, Shiers D, Large M. Tobacco use before, at, and after first-episode psychosis: a systematic meta-analysis. J Clin Psychiatry. 2012 Apr;73(4):468–75.

9. Gurillo P, Jauhar S, Murray RM, MacCabe JH. Does tobacco use cause psychosis? Systematic review and meta-analysis. The Lancet Psychiatry. 2015 Aug;2(8):718–25.

10. Kendler KS, Lönn SL, Sundquist J, Sundquist K. Smoking and schizophrenia in population cohorts of Swedish women and men: a prospective co-relative control study. Am J Psychiatry. 2015 Nov 1;172(11):1092–100.

11. Weiser M, Reichenberg A, Grotto I, Yasvitzky R, Rabinowitz J, Lubin G, et al. Higher rates of cigarette smoking in male adolescents before the onset of schizophrenia: a historical-prospective cohort study. Am J Psychiatry. 2004 Jul;161(7):1219–23.

12. Krishnadas R, Jauhar S, Telfer S, Shivashankar S, McCreadie RG. Nicotine dependence and illness severity in schizophrenia. Br J Psychiatry. 2012 Oct;201(4):306–12.

13. Gage SH, Hickman M, Heron J, Munafò MR, Lewis G, Macleod J, et al. Associations of cannabis and cigarette use with psychotic experiences at age 18: findings from the Avon Longitudinal Study of Parents and Children. Psychological Medicine. 2014 Dec;44(16):3435–44.

14. Wootton RE, Richmond RC, Stuijfzand BG, Lawn RB, Sallis HM, Taylor GMJ, et al. Evidence for causal effects of lifetime smoking on risk for depression and schizophrenia: a Mendelian randomisation study. Psychological Medicine. 2019;1–9.

15. Mustonen A, Ahokas T, Nordström T, Murray GK, Mäki P, Jääskeläinen E, et al. Smokin' hot: adolescent smoking and the risk of psychosis. Acta Psychiatr Scand. 2018;138(1):5–14.

16. Degenhardt L, Saha S, Lim CCW, Aguilar-Gaxiola S, Al-Hamzawi A, Alonso J, et al. The associations between psychotic experiences, and substance use and substance use disorders: Findings from the World Health Organisation World Mental Health Surveys. Addiction. 2018 May;113(5):924–34.

17. Bhavsar V, Jauhar S, Murray RM, Hotopf M, Hatch SL, McNeill A, et al. Tobacco smoking is associated with psychotic experiences in the general population of South London. Psychol Med. 2018 Jan;48(1):123–31.

18. Oh HY, Koyanagi A, Singh F, DeVylder J. Is smoking tobacco associated with psychotic experiences across racial categories in the United States? Findings from the Collaborative Psychiatric Epidemiological Surveys. Psychiatry Research. 2016 Dec;246:58–61.

19. Mackay DF, Anderson JJ, Pell JP, Zammit S, Smith DJ. Exposure to tobacco smoke in utero or during early childhood and risk of hypomania: Prospective birth cohort study. Eur Psychiatry. 2017;39:33–9.

20. Quinn PD, Rickert ME, Weibull CE, Johansson ALV, Lichtenstein P, Almqvist C, et al. Association between maternal smoking during pregnancy and severe mental illness in offspring. JAMA Psychiatry. 2017 Jun 1;74(6):589–96.

21. Jones HJ, Gage SH, Heron J, Hickman M, Lewis G, Munafò MR, et al. Association of Combined Patterns of Tobacco and Cannabis Use in Adolescence With Psychotic Experiences. JAMA Psychiatry. 2018 01;75(3):240–6.

22. van Gastel WA, MacCabe JH, Schubart CD, Vreeker A, Tempelaar W, Kahn RS, et al. Cigarette smoking and cannabis use are equally strongly associated with psychotic-like experiences: a cross-sectional study in 1929 young adults. Psychol Med. 2013 Nov;43(11):2393–401.

23. de Leon J, Diaz FJ. A meta-analysis of worldwide studies demonstrates an association between schizophrenia and tobacco smoking behaviors. Schizophr Res. 2005 Jul 15;76(2–3):135–57.

24. Hartz SM, Horton AC, Oehlert M, Carey CE, Agrawal A, Bogdan R, et al. Association Between Substance Use Disorder and Polygenic Liability to Schizophrenia. Biological Psychiatry. 2017 Nov 15;82(10):709–15.

25. Reginsson GW, Ingason A, Euesden J, Bjornsdottir G, Olafsson S, Sigurdsson E, et al. Polygenic risk scores for schizophrenia and bipolar disorder associate with addiction. Addiction Biology. 2018;23(1):485–92.

26. Carey CE, Agrawal A, Bucholz KK, Hartz SM, Lynskey MT, Nelson EC, et al. Associations between Polygenic Risk for Psychiatric Disorders and Substance Involvement. Front Genet. 2016;7:149.

27. Du Rietz E, Coleman J, Glanville K, Choi SW, O'Reilly PF, Kuntsi J. Association of Polygenic Risk for Attention-Deficit/Hyperactivity Disorder With Co-occurring Traits and Disorders. Biol Psychiatry Cogn Neurosci Neuroimaging. 2018;3(7):635–43.

28. Peyrot WJ, Milaneschi Y, Abdellaoui A, Sullivan PF, Hottenga JJ, Boomsma DI, et al. Effect of polygenic risk scores on depression in childhood trauma. Br J Psychiatry. 2014 Aug;205(2):113–9.

29. Mullins N, Power RA, Fisher HL, Hanscombe KB, Euesden J, Iniesta R, et al. Polygenic interactions with environmental adversity in the aetiology of major depressive disorder. Psychol Med. 2016 Mar;46(4):759–70.

30. Coleman JRI, Peyrot WJ, Purves KL, Davis KAS, Rayner C, Choi SW, et al. Genome-wide gene-environment analyses of major depressive disorder and reported lifetime traumatic experiences in UK Biobank. bioRxiv. 2018 Nov 1;247353.

31. Demontis D, Walters RK, Martin J, Mattheisen M, Als TD, Agerbo E, et al. Discovery of the first genome-wide significant risk loci for attention deficit/hyperactivity disorder. Nat Genet. 2019 Jan;51(1):63–75.

32. Wray NR, Ripke S, Mattheisen M, Trzaskowski M, Byrne EM, Abdellaoui A, et al. Genome-wide association analyses identify 44 risk variants and refine the genetic architecture of major depression. Nat Genet. 2018 May;50(5):668–81.

33. Ripke S, Neale BM, Corvin A, Walters JTR, Farh K-H, Holmans PA, et al. Biological insights from 108 schizophrenia-associated genetic loci. Nature. 2014 Jul;511(7510):421–7.

34. Davis KAS, Coleman JRI, Adams M, Allen N, Breen G, Cullen B, et al. Mental health in UK Biobank: development, implementation and results from an online questionnaire completed by 157 366 participants. BJPsych Open. 2018 May;4(3):83–90.

35. Bycroft C, Freeman C, Petkova D, Band G, Elliott LT, Sharp K, et al. The UK Biobank resource with deep phenotyping and genomic data. Nature. 2018;562(7726):203–9.

36. Ramírez J, Duijvenboden S van, Ntalla I, Mifsud B, Warren HR, Tzanis E, et al. Thirty loci identified for heart rate response to exercise and recovery implicate autonomic nervous system. Nat Commun. 2018 16;9(1):1947.

37. Hanscombe KB, Coleman JRI, Traylor M, Lewis CM. ukbtools: An R package to manage and query UK Biobank data. PLOS ONE. 2019 May 31;14(5):e0214311.

38. Choi SW, O'Reilly PF. PRSice-2: Polygenic Risk Score software for biobank-scale data. Gigascience. 2019 01;8(7).

39. Trotta A, Iyegbe C, Di Forti M, Sham PC, Campbell DD, Cherny SS, et al. Interplay between Schizophrenia Polygenic Risk Score and Childhood Adversity in First-Presentation Psychotic Disorder: A Pilot Study. Walss-Bass C, editor. PLOS ONE. 2016 Sep 20;11(9):e0163319.

40. Keller MC. Gene × Environment Interaction Studies Have Not Properly Controlled for Potential Confounders: The Problem and the (Simple) Solution. Biological Psychiatry. 2014 Jan 1;75(1):18–24.

41. Hatzimanolis A, Avramopoulos D, Arking DE, Moes A, Bhatnagar P, Lencz T, et al. Stress-Dependent Association Between Polygenic Risk for Schizophrenia and Schizotypal Traits in Young Army Recruits. Schizophr Bull. 2018 15;44(2):338–47.

42. Liuhanen J, Suvisaari J, Kajantie E, Miettunen J, Sarin A-P, Järvelin M-R, et al. Interaction between compound genetic risk for schizophrenia and high birth weight contributes to social anhedonia and schizophrenia in women. Psychiatry Res. 2018;259:148–53.

43. Association, A. (2013). Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5®). Washington, D.C.: American Psychiatric Publishing.

44. Howard DM, Adams MJ, Shirali M, Clarke T-K, Marioni RE, Davies G, et al. Genome-wide association study of depression phenotypes in UK Biobank identifies variants in excitatory synaptic pathways. Nat Commun. 2018 Apr 16;9(1):1–10.

45. Liu M, Jiang Y, Wedow R, Li Y, Brazel DM, Chen F, et al. Association studies of up to 1.2 million individuals yield new insights into the genetic etiology of tobacco and alcohol use. Nat Genet. 2019 Jan 14;

46. Howard DM, Adams MJ, Clarke T-K, Hafferty JD, Gibson J, Shirali M, et al. Genome-wide meta-analysis of depression identifies 102 independent variants and highlights the importance of the prefrontal brain regions. Nat Neurosci. 2019 Mar;22(3):343–52.

47. Fry A, Littlejohns TJ, Sudlow C, Doherty N, Adamska L, Sprosen T, et al. comparison of sociodemographic and health-related characteristics of UK Biobank participants with those of the general population. Am J Epidemiol. 2017 Nov 1;186(9):1026–34.

48. Duncan L, Shen H, Gelaye B, Meijsen J, Ressler K, Feldman M, et al. Analysis of polygenic risk score usage and performance in diverse human populations. Nat Commun. 2019 25;10(1):3328.